Mid Pharma Sector

Summary

Introduction

Mid Pharma companies are EU/US based pharmaceutical companies with 2005 annual revenues of <$10bn. An integral component of the Mid Pharma business model is securing access to promising new drugs through in-licensing and acquisition.

Highlights

Segmentation of the PharmaVitae Mid Pharma peer set of 22 companies into 5 clusters the 'Big 6', CNS-focus, CV-focus, small domestic and 'multi-business unit' clusters.Insight into the deep CNS cardiovascular therapeutic axis that runs through Mid Pharma with CNS (Lundbeck, Forest and Shire) and CV-focused (Servier, King, Menarini and Schwarz) players at either end of the spectrum with the 'Big 6' players located in the middle range, addressing a broad range of therapy areas.Analysis of how the level of externalization dependency varies within Mid Pharma, from highly committed in-licensors such as Forest to internally-sufficient operations such as Servier.

Scope

• Segmentation of the Mid Pharma market by key attributes including revenue size, therapy area and geographic focus
• Analysis of how dependent each Mid Pharma company is on externalization to support current portfolios
• Examination of which types of externalization strategy are most popular in the Mid Pharma peer set
• Case studies of how domestic players such as Menarini and Almirall are operating as conduits to the highly fragmented local markets of Europe

Reasons to Purchase

• Understand why the majority of Mid Pharma companies are committed to populating their portfolios by in-licensing and acquisition
• Identify which companies are appropriate licensing targets on the basis of their 'fit' according to their scale, therapeutic and geographic focus
• Learn which types of externalization strategy are responsible for the largest influx of product revenues to Mid Pharma

Contents

• Chapter 1 Executive Summary
  • Key findings
  • Mid Pharma - pharmaceutical companies with annual revenues under $10bn
  • Type of externalization strategy
  • Phase of externalization
  • Motives for external sourcing of products
  • Access to a broad palette of R&D opportunities
  • Externalization strategies as a mechanism for strategic redirection
  • Motives for source companies entering into externalization deals with Mid Pharma
  • Mid Pharma by revenues
  • Mid Pharma by therapy area
  • Segmentation analysis of Mid Pharma
  • Mid Pharma's dependence on externalization
  • Mid Pharma externalization sub-analysis
• Chapter 2 Mid Pharma - Committed To Externalization As An R&D Strategy
  • Mid Pharma - pharmaceutical companies with annual revenues under $10bn
  • Concept of external sourcing
  • Type of externalization strategy
  • Phase of externalization
  • Sample analysis of when externalization deals are actually executed
  • Motives for external sourcing of products
  • The cost of externalized R&D vs. internal R&D
  • Access to a broad palette of R&D opportunities
  • Externalization strategies as a mechanism for strategic redirection
  • Motives for source companies entering into externalization deals with Mid Pharma
• Chapter 3 Mid Pharma Segmentation
  • Mid Pharma by company
  • >$4 billion companies
  • $2-4 billion companies
  • <$2 billion companies
  • Mid Pharma company sales forecast
  • Mid Pharma company growth forecast
  • Mid Pharma by therapy area
  • Mid Pharma therapy area sales forecast
  • Mid Pharma therapy area growth forecast
  • Mid Pharma companies by CNS focus
  • Mid Pharma companies by cardiovascular focus
  • Mid Pharma segmentation by therapy area and size
  • Mid Pharma by geography
• Chapter 4 Mid Pharma Externalization Analysis
  • Mid Pharma externalization analysis
  • Externalization dependency by company
  • Segmentation of companies by externalization dependency
  • Company forecast for externalized products
  • Externalization dependency by therapy area
  • Therapy area forecast for externalized products
  • Domestic versus multi-region players
  • European Licensing Specialists
  • US Licensing Specialists
• Chapter 5 Mid Pharma Externalization Sub-Analysis
  • Mid Pharma externalization sub-analysis
  • Externalization revenues by deal type
  • Companies by externalization deal type
  • Marketing &development deals
  • Co-marketing deals
  • Co-promotion deals
  • Marketing deals
  • M&A deals
• Chapter 6 Appendix: Supporting Data
  • Exchange rates
• List Of Tables
  • Table 1: Mid Pharma companies ranked by sales, 2005
  • Table 2: Proportion of total sales by deal type, 2005
  • Table 3: Mid Pharma companies ranked by sales, 2005
  • Table 4: The PharmaVitae Mid Pharma peer set
  • Table 5: Mid Pharma therapy area sales, 2005
  • Table 6: Menarini's key domestic licensing deals
  • Table 7: Almirall's Top 10 domestic licensing deals
  • Table 8: Forests Major Licensing Deals
  • Table 9: King's Major Licensing Deals
  • Table 10: Proportion of total sales by deal type, 2005
  • Table 11: Exchange rates*, 2004
• List Of Figures
  • Figure 1: Mid and Big Pharma CAGRs, 2001-04, 2004-07f and 2007f-10f
  • Figure 2: % Dependency of revenues on externally sourced products
  • Figure 3: Absolute growth ($bn) of Mid Pharma peer set, 2005-10f
  • Figure 4: Mid Pharma ranked by 2005 ethical sales
  • Figure 5: Big Pharma vs. Mid Pharma therapy area split
  • Figure 6: Segmentation of Mid Pharma by therapy area focus and size ($m), 2005
  • Figure 7: Mid Pharma sales by source, 2001-10f
  • Figure 8: Mid Pharma external discovery revenue dependency, 2005
  • Figure 9: Mid Pharma externally sourced sub-classification
  • Figure 10: Mid Pharma external discovery sales by deal type, 2005
  • Figure 11: Mid Pharma company by externalization deal type, 2005
  • Figure 12: Mid &Big Pharma ethical sales, 2001-10f
  • Figure 13: Mid and Big Pharma CAGRs, 2001-04, 2004-07f and 2007f-10f
  • Figure 14: CAGRs for Mid Pharma peer set, 2004-10f
  • Figure 15: % Dependency of revenues on externally sourced products
  • Figure 16: Absolute growth ($bn) of Mid Pharma peer set, 2005-10f
  • Figure 17: A product is defined as externally sourced on the basis of being discovered in an external R&D pipeline
  • Figure 18: Stage of licensing for top 50 deals in terms of 2005 revenues
  • Figure 19: Mid Pharma ranked by 2005 ethical sales
  • Figure 20: Mid Pharma historical and sales forecasts, 2001-10f
  • Figure 21: Mid Pharma absolute growth, 2005-10f
  • Figure 22: Big Pharma vs. Mid Pharma therapy area split
  • Figure 23: Mid Pharma sales by therapy area, 2005
  • Figure 24: Mid Pharma absolute growth by therapy area, 2005-10f
  • Figure 25: Percentage of 2005 sales derived from CNS products for Mid Pharma
  • Figure 26: Percentage of 2005 sales derived from CV products for Mid Pharma
  • Figure 27: Percentage of revenues from top four therapy areas, 2005
  • Figure 28: Distribution of CNS- and CV-focused players
  • Figure 29: Segmentation of Mid Pharma by therapy area focus and size ($m), 2005
  • Figure 30: Segmentation of Mid Pharma by therapy area focus and size ($m), 2010f
  • Figure 31: Mid Pharma 2005 revenues by geography
  • Figure 32: Mid Pharma ranked by US focus, 2005
  • Figure 33: Classification of Mid Pharma peer set
  • Figure 34: Mid Pharma sales by source, 2001-10f
  • Figure 35: Absolute growth ($bn) of Mid Pharma peer set by source, 2005-10f
  • Figure 36: Mid Pharma external discovery revenue dependency, 2005
  • Figure 37: Segmentation of Mid Pharma by externalization dependency and size, 2005
  • Figure 38: Mid Pharma externally sourced revenues by company, 2005
  • Figure 39: Mid Pharma revenues from externally source products by company, 2001-10f
  • Figure 40: Externalization dependency by therapy area
  • Figure 41: Mid Pharma 2005 externally sourced sales by therapy area, 2005
  • Figure 42: Externally sourced revenues by therapy area, 2001-10f
  • Figure 43: Regional focus of Mid Pharma externalization
  • Figure 44: Mid Pharma externally sourced sub-classification
  • Figure 45: Mid Pharma external discovery sales by deal type, 2005
  • Figure 46: Mid Pharma company by externalization deal type, 2005
  • Figure 47: Proportion of externally sourced sales from marketing &development, 2005
  • Figure 48: Proportion of externally sourced sales from co-marketing, 2005
  • Figure 49: Proportion of externally sourced sales from co-promotion, 2005
  • Figure 50: Proportion of externally sourced sales from marketing, 2005
  • Figure 51: Proportion of externally sourced sales from corporate M&A, 2005